Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Stefan Hantel"'
Autor:
Stefan Kaspers, Stuart J. Pocock, Stefan D. Anker, Michaela Mattheus, Silvio E. Inzucchi, Søren S Lund, Maximilian von Eynatten, Christoph Wanner, Jyothis T. George, Waheed Jamal, Stefan Hantel, Bernard Zinman, Odd Erik Johansen, David Fitchett, Ulrich Elsasser, Darren K. McGuire
Publikováno v:
The Lancet Diabetes & Endocrinology. 8:949-959
Patients with type 2 diabetes and atherosclerotic cardiovascular disease are at high clinical risk. We assessed the effect of the sodium-glucose co-transporter-2 inhibitor, empagliflozin, on total cardiovascular events and admissions to hospital in t
Autor:
Christoph Wanner, Stefan Hantel, Maximilian von Eynatten, Tomoo Okamura, Masaomi Nangaku, Takashi Kadowaki, Audrey Koitka-Weber
Publikováno v:
Journal of Diabetes Investigation
Journal of Diabetes Investigation, Vol 10, Iss 3, Pp 760-770 (2019)
Journal of Diabetes Investigation, Vol 10, Iss 3, Pp 760-770 (2019)
Aims/Introduction In the EMPA‐REG OUTCOME® trial, empagliflozin added to standard of care improved clinically relevant kidney outcomes by 39%, slowed progression of chronic kidney disease, and reduced albuminuria in patients with type 2 diabetes a
Autor:
Rosa-Maria Espadero, Bernard Zinman, David Fitchett, Christoph Wanner, Gisle Langslet, Stefan Hantel, Odd Erik Johansen
Publikováno v:
Diabetes & Vascular Disease Research
Objective: It is well established that higher low-density lipoprotein (LDL)-cholesterol levels are associated with increased cardiovascular risk. We analyzed whether effects of empagliflozin on cardiovascular outcomes varied by different LDL-choleste
Publikováno v:
Diabetologia
Aims/hypothesis In addition to beneficial effects on glycaemia and cardiovascular death, empagliflozin improves adiposity indices. We investigated the effect of empagliflozin on aminotransferases (correlates of liver fat) in individuals with type 2 d
Autor:
Bernard Zinman, John M. Lachin, Silvio E. Inzucchi, Christoph Wanner, Philippe van de Borne, Javed Butler, Odd Erik Johansen, Jyothis T. George, Stefan Hantel, Hans-Juergen Woerle, David Fitchett
Aims Empagliflozin reduced the risk of cardiovascular (CV) death and heart failure (HF) hospitalizations in patients with type 2 diabetes (T2D) and established CV disease (CVD) in the EMPA-REG OUTCOME (R) trial. We investigated whether the benefit of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::625177926dc0b6cf8b9fea61cc63d41b
https://www.bib.irb.hr/1120990
https://www.bib.irb.hr/1120990